Phase
Condition
Phenylketonuria
Tyrosinemia
Treatment
GMP Intervention Product
Clinical Study ID
Ages > 3 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male or female
Over 3 years of age
Patients diagnosed with any phenotype of PKU characterised by hyperphenylalaninaemiaor patients diagnosed with tyrosinaemia
Have been compliant in taking at least one protein substitute, providing at least 15g protein equivalents, for at least 1 month prior to trial commencement
Have a prescribed daily phenylalanine or phenylalanine and tyrosine allowance forPKU or TYR respectively
Written or electronic informed consent from patient, and/or from parent/caregiver ifapplicable
Participants who are anticipated to be able to take at least one sachet of GMPProduct per day
Exclusion
Exclusion Criteria:
Pregnant or lactating
Requiring parenteral nutrition
Major hepatic or renal dysfunction
Participation in other studies within 1 month prior to entry of this study
Allergy to any of the study product ingredients
Investigator concern around willingness/ability of patient or parent/caregiver tocomply with protocol requirement
Study Design
Connect with a study center
Birmingham Women and Children's Hospital
Birmingham 2655603,
United KingdomActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.